Medshine Discovery Inc. has disclosed fused quinazoline compounds acting as son of sevenless homolog 1 (SOS1)/GTPase KRAS (G12C mutant) interaction inhibitors reported to be useful for the treatment of solid tumors.

Xinthera Inc. has disclosed tricyclic poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.

Tarapeutics Science Inc. has identified phosphatidylinositol 3-kinase δ (PI3Kδ) inhibitors reported to be useful for the treatment of cancer, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease (COPD) and systemic lupus erythematosus.

Beigene Ltd. has identified IL-17A/IL-17 receptor A (IL-17RA) interaction inhibitors reported to be useful for the treatment of cancer, psoriasis, rheumatoid arthritis, spondyloarthritis and multiple sclerosis.

Beijing Earthwise Technology Co. Ltd. has synthesized fused pyridazinone compounds acting as protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.

Gilead Sciences Inc. has described GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Nanjing Zaiming Pharmaceutical Co. Ltd. has identified DNA polymerase θ (POLθ) inhibitors reported to be useful for the treatment of cancer.

Suzhou Zelgen Biosciences Co. Ltd. has synthesized GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of pancreatic cancer.

Scinnohub Pharmaceutical Co. Ltd. has identified S-adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors reported to be useful for the treatment of cancer. 

Shanghai Ringene Biopharma Co. Ltd. has synthesized CDK7/cyclin H inhibitors reported to be useful for the treatment of cancer, hemolytic anemia, rheumatoid arthritis, psoriasis, systemic lupus erythematosus, sepsis, idiopathic thrombocytopenic purpura and ulcerative colitis, among others.